|
1
|
5
|
CTNNB1–DVL1–DVL3–PPM1A complex (80%), HSPB1–PPA1–PPA1–SETDB1–TP53–WIPI1 complex (66.67), EEF1A1–MDH2–WARS complex (66.67), transforming growth factor–SMAD complex (66.67)
|
DVL2, ‘CTNNB1’ ‘PPM1A’ ; ‘SMAD3’ ‘TP53’ ‘PPA1’ ‘PPA1’; YWHAG’ ‘EEF1A1’; ‘EEF1A1’ ‘SMAD2’
|
Enzyme linked receptor protein signaling pathway (GO:0007167 ) (5.9E–11)
|
Cytosol (GO:0005829) (3.4E–11)
|
Enzyme binding (GO:0019899) (1.5E–12)
|
Colorectal cancer (2.9E–11), Pathways in cancer(1.2E–10)
|
|
2
|
6
|
CDH1–CTNNB1–PTPN1 complex(50), transforming growth factor–SMAD complex (66.67), HSPB1–PPA1–PPA1–SETDB1–TP53–WIPI1 complex (66.67)
|
DVL2 SMAD3 TP53 YWHAG
|
Response to organic substance (GO:0010033) (4.2E–14)
|
Cytosol (GO:0005829) (2.5E–25)
|
Protein kinase activity (GO:0004672) (1.8E–10)
|
Pathways in cancer (6.1E–19)
|
|
3
|
8
|
MARCKS–NMT1–TP53 complex (66.67), transforming growth factor–SMAD complex (75), CTNNB1–DVL1–DVL3–PPM1A complex (50)
|
CTNNB1 SMAD3 TP53 YWHAG TP53 SMAD2
|
Protein amino acid phosphorylation (GO:0006468) (4.1E–14)
|
Cytosol (GO:0005829) (3.8E–23)
|
Protein serine/threonine kinase activity (GO:0004674) (1.7E–11)
|
Chronic myeloid leukemia (5.7E–16)
|
|
4
|
11
|
p300–MDM2–p53 protein complex (63.64), CDH1–CTNNB1–PTPN1 complex (60)
|
HDAC1 TP53 ESR1 TP53 CTNNB1
|
Positive regulation of nitrogen compound metabolic process (GO:0051173) (4.1E–20)
|
Nucleoplasm (GO:0005654) (2.6E–18)
|
Transcription factor binding (GO:0008134) (1.5E–15)
|
Prostate cancer (2.0E–12)
|
|
5
|
15
|
p300–MDM2–p53 protein complex (72.73), CASP8–MAPK1–MAPK3–PEA15–RPS6KA3 complex (60),CDH1–CTNNB1–PTPN1 complex (75), EP300–HOXB6–HOXB7 complex (66.67)
|
EP300 HDAC1 TP53 ESR1 LCK HSP90AA1 MAPK1 MAPK3 EP300 TP53 EP300 TP53 FOXO1 SMAD4 EP300 SMAD2 CTNNB1 PTPN1 HGS EP300 EEF1A1 SMAD2
|
Positive regulation of macromolecule metabolic process (GO:0010604) (4.5E–34)
|
Nucleoplasm (GO:0005654) (3.1E–34)
|
Transcription regulator activity (GO:0030528) (7.6E–26)
|
Chronic myeloid leukemia (9.1E–26)
|
|
6
|
20
|
Smad protein complex (53.33), FOXO–SMAD complex (60), transforming growth factor–SMAD complex (75), CDH1–CTNNB1–PTPN1 complex (75)
|
SMAD3 SMAD2 LCK HSP90AA1 TP53 YWHAG CTNNB1 SMAD2
|
Positive regulation of cellular biosynthetic process (GO:0031328) (6.8E–23)
|
Cytosol (GO:0005829) (3.9E–15)
|
Enzyme binding (GO:0019899) (1.5E–20)
|
Adherens junction (1.2E–16)
|
|
7
|
25
|
EEF1A1–MDH2–WARS complex (66.67), CTNNB1–DVL1–DVL3–PPM1A complex (66.67)
|
DVL2 CTNNB1 PPM1A SMAD3 TP53 PPA1 PPA1 YWHAG EEF1A1 EEF1A1 SMAD2
|
Enzyme linked receptor protein signaling pathway (GO: 0007167) (2.5E–15)
|
Cytosol (GO:0005829) (6.1E–20)
|
SMAD binding (2.2E–13) (GO:0046332)
|
Pathways in cancer (3.5E–21)
|
|
8
|
26
|
CDK5R2–CHN1–ERBB2 complex (66.67), EEF1A1–MDH2–WARS complex(66.67)
|
SMAD3 TP53 YWHAG SMAD2
|
Response to organic substance (GO:0010033) (4.9E–12)
|
Cytosol (GO:0005829) (3.9E–20)
|
Enzyme binding (GO:0019899) (8.0E–16)
|
Colorectal cancer(6.4E–14)
|
|
9
|
36
|
SMAD1–SMAD4–ECSIT2 containing complex (80), CDH1–CTNNB1–PTPN1 complex (75), p300–MDM2–p53 protein complex (81.82)
|
‘BRCA1’ ‘CTNNB1’ ‘ECSIT’ ‘EP300’ ‘ESR1’ ‘HDAC1’ ‘MDM2’ ‘PTPN1’ ‘RB1’ ‘SMAD1’ ‘SMAD4’ ‘SP1’ ‘TP53’ ‘UBE2Z’
|
Positive regulation of cellular biosynthetic process (GO:0031328) (7.8E–37)
|
Nuclear lumen (GO:0031981) (3.0E–27)
|
Transcription regulator activity (1.7E–30) (GO:0030528)
|
Pathways in cancer(2.6E–30)
|
|
10
|
39
|
FOXO–SMAD complex (60), EEF1A1–MDH2–WARS complex (66.67), CDH1–CTNNB1–PTPN1 complex (75)
|
‘CDH2’ ‘CTNNB1’ ‘EEF1A1’ ‘FOXO1’ ‘FOXO3’ ‘SMAD1’ ‘SMAD4’ ‘YWHAG’
|
Cell cycle (GO:0007049) (1.2E–30)
|
Nucleoplasm (GO:0005654) (8.8E–59)
|
Transcription factor binding (GO:0008134) (1.5E–25)
|
Cell cycle (1.6E–18)
|
|
11
|
40
|
ERBB2IP–ZFYVE9 containing complex, p300–MDM2–p53 protein complex (72.73), CDK7–cyclin H complex (60)
|
‘AR’ ‘BRCA1’ ‘CDK2’ ‘EP300’ ‘ERBB2IP’ ‘ESR1’ ‘HDAC1’ ‘MDM2’ ‘MNAT1’ ‘SP1’ ‘TBP’ ‘TP53’ ‘UBE2I’
|
Positive regulation of macromolecule metabolic process (GO:0010604) (1.6E–29)
|
Nuclear lumen(GO:0031981) (1.3E–19)
|
Transcription activator activity (GO:0016563) (3.2E–14)
|
Pathways in cancer(3.3E–16)
|
|
12
|
10
|
CDK7–cyclin H complex (80), CASP8–MAPK1–MAPK3–PEA15–RPS6KA3 complex (80), ITPR1–STARD13–TXNDC4 complex (66.67), PIN1–TP53 complex(66.67)
|
‘AR’ ‘CASP8’ ‘CDK2’ ‘CDK7’ ‘HMGB1’ ‘ITPR1’ MAPK1’ ‘MAPK3’ ‘MDM2’ ‘MNAT1’ ‘PEA15’ ‘PIN1’ ‘TP53’ ‘TP73’
|
Positive regulation of gene expression (GO:0010628) (1.0E–23)
|
Transcription factor complex (GO:0005667) (9.8E–13)
|
Enzyme binding (GO:0019899) (9.7E–21)
|
Pathways in cancer (7.0E–26)
|
|
13
|
51
|
HSPA1A–TP53 complex (100), ATXN1–C1orf94–DAZAP2–RBPMS–UBQLN4 containing complex (66.67), p300–MDM2–p53 protein complex (80)
|
‘ATXN1’ ‘BAT2’ ‘BRCA1’ ‘DAZAP2’ ‘EP300’ ‘ERBB2IP’ ‘ESR1’ ‘HDAC1’ ‘HSPA1A’ ‘MDM2’ ‘SP1’ ‘TBP’ ‘TP53’ ‘UBE2I’ ‘UBQLN4’
|
Positive regulation of cellular biosynthetic process (GO:0031328) (4.7E–32)
|
Nucleoplasm (GO:0005654) (1.7E–28)
|
Transcription regulator activity (GO:0030528) (3.2E–20)
|
Pathways in cancer (4.2 E–24)
|
|
14
|
3
|
CDH1–CTNNB1–PTPN1 complex (75), EEF1A1–MDH2–WARS complex(66.67)
|
‘CDH2’ ‘CTNNB1’ ‘EEF1A1’ ‘PTPN1’ ‘YWHAG’
|
Positive regulation of macromolecule metabolic process (GO:0010604) (8.7E–28)
|
Nucleoplasm (GO:0005654) (2.0E–18)
|
Transcription factor binding (GO:0008134) (1.3E–18)
|
Neurotrophin signaling pathway (2.3E–12)
|
|
15
|
38
|
COP9 signalosome (CSN) (70), mutant p53/NF-Y protein (mutp53/NF-Y) complex (66.67), TP53–TP73 complex (66.67), HSPB1–PPA1–PPA1–SETDB1–TP53–WIPI1 complex (66.67)
|
‘COPS3’ ‘COPS4’ ‘COPS5’ ‘COPS6’ ‘COPS7A’ ‘COPS8’ ‘CREBBP’ ‘EP300’ ‘GPS1’ ‘NFYA’ ‘PPA1’ ‘SMAD3’ ‘SP1’ ‘TP53’ ‘TP73’ ‘WT1’
|
Positive regulation of nitrogen compound metabolic process (GO:0051173) (6.9E–22)
|
Cytosol (GO:0005829) (1.4E–10)
|
Enzyme binding (GO:0019899) (2.8E–18)
|
Pathways in cancer (7.0E–20)
|
|
16
|
21
|
MDM2–PML–PML–SUMO1–SUZ12 complex (80), SUMO1 activation complex (66.67), p300–MDM2–p53 protein complex (80)
|
‘AR’ ‘BRCA1’ ‘DAXX’ ‘EP300’ ‘ESR1’ ‘HDAC1’ ‘MDM2’ ‘PIAS1’ ‘PML’ ‘RB1’ ‘SP1’ ‘SUMO1’ ‘TP53’ ‘UBE2I’
|
Positive regulation of transcription (5.7E–34)
|
Organelle lumen (GO:0043233) (8.3E–34)
|
Transcription regulator activity (GO:0030528) (4.9E–39)
|
Pathways in cancer (3.9E–21)
|
|
17
|
30
|
CDH1–CTNNB1–PTPN1 complex (75), PKD1–PKD2 complex (66.67), EEF1A1–MDH2–WARS complex (66.67)
|
‘CDH2’ ‘CTNNB1’ ‘EEF1A1’ ‘PKD1’ ‘PTPN1’ ‘YWHAG’
|
Positive regulation of nitrogen compound metabolic process (GO:0051173) (1.0E–17)
|
Cell projection (GO:0042995) (9.0E–8)
|
Enzyme binding (GO:0019899) (2.1E–13)
|
Adherens junction (1.5E–18)
|
|
18
|
13
|
TP53–TP73 complex (66.67), p300–MDM2–p-53 protein complex (72.73)
|
‘BRCA1’ ‘CREBBP’ ‘EP300’ ‘ESR1’ ‘HDAC1’ ‘MDM2’ ‘SP1’ ‘TBP’ ‘TP53’ ‘TP73’ ‘WT1’
|
Positive regulation of cellular biosynthetic process (GO:0031328) (3.1E–25)
|
Nuclear lumen (7.3E–24)
|
Transcription regulator activity (GO:0030528) (2.2E–24)
|
Prostate cancer (8.5E–9)
|
